Stay updated on Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe update shows Revision: v3.4.2 replacing v3.4.1, which appears to be a minor version revision without changes to study content, eligibility, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; a minor update that does not affect study data or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page now shows a glossary and metadata labels have been updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the previous Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4, which appears to be a minor backend/format update without changes to the study content or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedFooter updates show a new Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.